Literature DB >> 22773242

Extraglomerular C3 deposition and metabolic impacts in patients with IgA nephropathy.

Isao Ohsawa1, Gaku Kusaba, Masaya Ishii, Nobuyuki Sato, Hiroyuki Inoshita, Kisara Onda, Azusa Hashimoto, Seiji Nagamachi, Hiyori Suzuki, Mamiko Shimamoto, Hiroyuki Ohi, Satoshi Horikoshi, Yasuhiko Tomino.   

Abstract

BACKGROUND: The aim of the present study was to explore the significance of extraglomerular (Bowman's capsule and/or arteriole) C3 (ex-C3) deposits in IgA nephropathy (IgAN).
METHODS: One hundred and seventy patients with IgAN were divided into two groups: Group A (n=79), patients who did not have ex-C3 deposits, and Group B (n=91), patients who had ex-C3 deposits.
RESULTS: At the time of renal biopsy, Group B was characterized by a marked increase in diastolic blood pressure, total cholesterol, triglyceride and low-density lipoprotein-cholesterol compared with those of Group A. After 4 years, the estimated glomerular filtration rate (eGFR) in Group B was significantly worse than that of Group A. Upon examination by electron microscopy, the arteriolar dense deposits in Group B were found to occur in significantly higher amounts than in Group A. One hundred and thirty-four patients underwent a 3-year follow-up study after intervention and were re-divided by therapeutic factors as follows: 'conventional therapy', treatment with anti-hypertensive drugs and/or anti-platelet drugs, and 'aggressive therapy', additional treatment with either tonsillectomy or corticosteroid. Patients treated with conventional therapy in Group B had significantly higher body mass index and levels of C3 and CH50 compared with other Groups. Aggressive therapy was significantly effective in urinary protein reduction in both Group A and Group B. Except for the patients who received aggressive therapy in Group A, the levels of the eGFR gradually declined.
CONCLUSIONS: It appears that IgAN patients who have ex-C3 deposits have worse clinical outcomes.

Entities:  

Keywords:  C3; IgA nephropathy; atherosclerosis; dyslipidemia; metabolic syndrome

Mesh:

Substances:

Year:  2012        PMID: 22773242     DOI: 10.1093/ndt/gfs262

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  7 in total

1.  Impact of Body Mass Index on Progression of IgA Nephropathy Among Japanese Patients.

Authors:  Mamiko Shimamoto; Isao Ohsawa; Hiyori Suzuki; Atsuko Hisada; Seiji Nagamachi; Daisuke Honda; Hiroyuki Inoshita; Yoshio Shimizu; Satoshi Horikoshi; Yasuhiko Tomino
Journal:  J Clin Lab Anal       Date:  2014-08-17       Impact factor: 2.352

Review 2.  Biologics for the treatment of autoimmune renal diseases.

Authors:  Stephen R Holdsworth; Poh-Yi Gan; A Richard Kitching
Journal:  Nat Rev Nephrol       Date:  2016-03-07       Impact factor: 28.314

3.  Correlation of immunostaining findings with demographic data and variables of Oxford classification in IgA nephropathy.

Authors:  Hamid Nasri; Shahram Sajjadieh; Saeed Mardani; Ali Momeni; Alireza Merikhi; Yahya Madihi; Alaleh Ghiessari; Afsoon Emami Naieni
Journal:  J Nephropathol       Date:  2013-07-01

Review 4.  Primary glomerulonephritis: A review of important recent discoveries.

Authors:  Jürgen Floege
Journal:  Kidney Res Clin Pract       Date:  2013-07-26

5.  Immunofluorescence deposits in the mesangial area and glomerular capillary loops did not affect the prognosis of immunoglobulin a nephropathy except C1q:a single-center retrospective study.

Authors:  Lingzhi Wu; Di Liu; Ming Xia; Guochun Chen; Yu Liu; Xuejing Zhu; Hong Liu
Journal:  BMC Nephrol       Date:  2021-01-29       Impact factor: 2.388

Review 6.  The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?

Authors:  Felix Poppelaars; Bernardo Faria; Wilhelm Schwaeble; Mohamed R Daha
Journal:  J Clin Med       Date:  2021-10-14       Impact factor: 4.241

Review 7.  Chronic kidney disease: a review of proteomic and metabolomic approaches to membranous glomerulonephritis, focal segmental glomerulosclerosis, and IgA nephropathy biomarkers.

Authors:  Amir Taherkhani; Reyhaneh Farrokhi Yekta; Maede Mohseni; Massoud Saidijam; Afsaneh Arefi Oskouie
Journal:  Proteome Sci       Date:  2019-12-20       Impact factor: 2.480

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.